Industry · Healthcare & MedTech
Revenue intelligence for
healthcare and medtech.
Procurement committees, clinical validation and regulatory review each add weeks. The proposal stage alone commonly runs 40 days, and negotiation adds nearly a month more.
Benchmarks compiled from published 2025–2026 industry research. Treat as directional, not prescriptive — your own trailing four-quarter average is the only benchmark that matters.
The signals that matter here
Generic deal scoring gets this wrong.
Most deal-scoring models were built on a mid-market SaaS motion and quietly assume it. In healthcare and medtech, the signals that actually predict a close are different — and a model that does not know that will confidently mislead you.
Sector-specific signals
· Clinical validation and pilot outcomes
· Procurement committee composition
· Compliance and data-protection review
· Value-analysis committee timing
The verdict
Healthcare has a healthy win rate but a back-loaded cycle. Most of the time is spent after the buyer has already decided — which means engagement recency in late stages is a weaker signal here than elsewhere.
What Quotarider does about it
Deal health weighted for a ~125 days cycle. Commission modelled against the actual structure — not a generic percentage. And a sourcing cutoff calculated from your real cycle length, so you know the last day a deal can be started and still land this period.
The three suites
Everything, tuned for healthcare and medtech.
Sales Suite
Deal health scored against a ~125 days cycle. Commission modelled at 6–12% of contract value. Activity measured against the pace your quota actually needs.
Explore →
Marketing Suite
Campaign ROI against your real margin, lead scoring tuned to your ICP, and attribution against closed revenue rather than last-click.
Explore →
Revenue Suite
Both, unified. One forecast built from pipeline velocity and campaign generation together — rather than two that disagree.
Explore →
Start now
Your number is due either way.
Free tier, no card, sixty seconds.